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INTRODUCTION 
Lenalidomide is a novel oral immunomodulatory 
derivative of thalidomide with potent activity and with a 
much improved toxicity profile to the parent compound.  
Thalidomide has a potential to treat inflammatory and 
neoplastic condition like multiple myeloma but was 
withdrawn from the market after its teratogenic effects 
were established.1Lenalidomide, a potent analogue of 
thalidomide was developed with improvement in safety 
and efficacy than the parent drug, thalidomide.It was 
created using thalidomide as a template by adding an 
amino group to the 4th carbon of the phthaloyl ring and 
removal of a carbonyl group. 
Lenalidomide possesses immunomodulatory, anti-
angiogenic, antineoplastic and anti-inflammatory 
activities. Lenalidomide has been extensively studied and 
approved for refractory / relapsing multiple myeloma 
(MM), mantle cell lymphoma (MCL) and 
myelodysplastic syndromes (MDS).2 
Multiple myeloma is a B cell malignancy characterized 
by accumulation of plasma cell clone in the bone 
marrow, monoclonal protein in serum and/or urine, 
reduced immunoglobulin levels and lytic bone 
disease.3Alkylating agents, anthracyclines and 
corticosteroids were commonly used drugs in multiple 
myeloma which extended patient’s survival to median 3-
4 yearsas compared to median survival of 4-5 years with 
high dose of these drugs followed by autologous 
transplantation.4 Due to the development of tumor cell 
resistance to all therapies, multiple myeloma still 
remains incurable, requiring further study on novel 
treatment strategies.5 The survival in MM patients has 
improved significantly in the past decade due to the 
introduction of novel agents including 
immunomodulatory drugs 
(thalidomide, lenalidomide and pomalidomide), 
proteasome inhibitors (bortezomib, carfilzomib, 
marizomib and ixazomib citrate), monoclonal antibodies 
(elotuzumab, siltuximab, daratumumab and BT-062), 
and drugs affecting an interaction with the tumor 
microenvironment (anti-VLA4 monoclonal antibody, 
chemokine CXCR4 inhibitor AMD-3100 and selectin 
inhibitor GMI-1070).6-8 
Lenalidomide has been found to be more potent in the 
stimulation of T-cell proliferation and INF gamma and 
IL-2 production than thalidomide, whereas both 
thalidomide and pomalidomide, another thalidomide 
analogue, have been found to be more potent at 
inhibiting sprout formation than lenalidomide when 
antiangiogenic properties were assessed in a human 
umbilical explant model. Thalidomide was associated 
with dose-limiting toxicities including somnolence, 
constipation, neuropathy, and increased incidence of 
venothromboembolism (VTE), especially when 
combined with dexamethasone9.No clinical trials directly 
comparing these agents have been performed, 
lenalidomide appears to have a lower incidence of 
constipation, peripheral neuropathy, and somnolence 
than thalidomide.2 
Structure  
 
(RS)-3-(4-Amino-1-oxo 1,3-dihydro-2H-isoindol- 2-
yl)piperidine-2,6-dione 
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Mechanism of action 
Lenalidomide haspotent immunomodulatory, 
antiangiogenic and antineoplastic properties.10,11 Novel 
biological agents target not only the MM cell, but also 
MM cell–host interactions, cytokines, and their sequelae 
in the bone marrowmilieu. Lenalidomide is several 
thousand fold more potent than thalidomide at inhibiting 
TNFα/il-1β secretion from mononuclear cells stimulated 
with lipopolysaccharide. The combination of 
lenalidomide and corticosteroid synergizes the inhibition 
of cell proliferation and the induction of apoptosis. 
Lenalidomide may inhibit MM cell growth by several 
different mechanisms.5,12-14 Itdirectly induces tumor cell 
apoptosis and/or growth arrest (A); enhances NK and/or 
NK cell activity via activation of cd28/nf-at2 pathway 
(B); inhibits MM cell adhesion to host microenvironment 
(C); inhibits angiogenesis (D); inhibits 
osteoclastogenesis (E); inhibits cytokine secretion (F). 
 
 
Figure 1: Potential mechanisms of action of anti-MM activity of lenalidomide.2 
Pharmacokinetics 
Lenalidomide is rapidly absorbed following oral 
administration and food has no change in AUC but Cmax 
may be reduced to 36%. Plasma protein binding is 
approximately 30%. Lenalidomide -undergoes limited 
metabolism with two identified metabolites hydroxy-
lenalidomide and n-acetyl-lenalidomide; each constitutes 
less than 5% of parent drug levels in circulation. 
Unchanged lenalidomide, about 67%, is the predominant 
circulating component primarily excreted by renal route. 
The mean half-life of lenalidomide is 3 hours in healthy 
subjects and 3 to 5 hours in patients with MM, MDS or 
MCL.15 
Clinical efficacy 
A multicenter, open-label, phase 2 study of lenalidomide 
plus low-dose dexamethasone in Chinese patients with 
relapsed/refractory multiple myeloma (RRMM) 
conducted to assess the efficacy, safety, and 
pharmacokinetics of lenalidomide plus low-dose 
dexamethasone showed high response rate and 
acceptable safety profile in heavily pretreated Chinese 
patients with RRMM, including those with renal 
impairment and IgD subtype.15,16 
Two phase III randomized studies validated the role of 
lenalidomide in combination with dexamethasone for the 
treatment of relapsed/refractory MM patients showed 
overall response rate of 83%, including 29% of complete 
response as seen by negative immunoﬁxation on the 
serum and urine.
17 
The toxicity profile of the treatment 
was in line with that reported in previous studies and led 
to dose reductions and treatment interruption in 44% and 
17% of patients, respectively.18 These results led the US 
Food and Drug Administration (FDA) on June 29, 2006 
to grant approval to lenalidomide in combination with 
dexamethasone in patients with MM who have received 
one prior therapy. 
In a phase I clinical dose-escalation (5 mg/day, 10 
mg/day, 25 mg/day, and 50 mg/day) study of 
lenalidomideat Dana-Farber cancer institute, no dose-
limiting toxicity (DLT) was observed in patients treated 
at any dose level within the first 28 days; however, grade 
3 myelosuppression developed after day 28 in all 13 
patients treated with 50 mg/day lenalidomide. Dose 
reduction to 25 mg/day was well tolerated in 12 patients 
and therefore considered to be the maximal tolerated 
dose (MTD). Most importantly, no significant 
somnolence, constipation, or neuropathy, the most 
common toxicities of thalidomide, has been seen in any 
cohort.19 
A multicentric, open-label, randomized phase II study 
evaluated 2 dose regimens of lenalidomide for relapsed, 
refractory MM with either 30 mg once-daily or 15 mg 
twice-daily oral lenalidomide for 21 days of every 28-
day cycle.  Responses were evaluated according to 
European group for blood and marrow transplantation 
(EBMT) criteria and overall response rate to 
lenalidomide alone was 25%; 24% for 30 mg once-daily 
and 29% for 15 mg twice-daily cohort. This study 
indicates that lenalidomide is active and well tolerated in 
relapsed, refractory myeloma, with the 30-mg once-daily 
regimen providing the basis for future studies as 
monotherapy and with dexamethasone.5,19 
Two double blind, multicentric phase III clinical trials 
showed significant improvement with lenalidomide plus 
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dexamethasone compared to dexamethasone in overall 
response. In this study patients with relapsed or 
refractory MM not resistant to dexamethasonewere 
treated with dexamethasone40 mg daily on days 1–4, 9–
12, and 17–20 every 28 days and were randomized to 
receive either lenalidomide 25 mg daily orally on days 
1–21 every 28 days or placebo. Results show significant 
improvement with lenalidomide plus dexamethasone 
compared to dexamethasone alone in overall response.5 
Available in four dosage strengths - 5mg, 10mg, 15mg 
and 25mg hard capsules. For multiple myeloma, initially, 
25 mg orally daily with water (as a single 25 mg capsule) 
on days 1 to 21 of a 28-day cycle; co-administer 
dexamethasone 40 mg/day orally on days 1 to 4, 9 to 12, 
and 17 to 20 of each 28-day cycle for the first 4 cycles, 
then 40 mg/day orally on days 1 to 4 every 28 days; 
continue therapy, with dose adjustments for toxicities, 
until disease progression. The dose of lenalidomide may 
vary from patient to patient for several reasons 
depending on the nature and stage of the person’s 
myeloma, any side effect a person may have and how the 
myeloma is responding to treatment.20-22 
Drug interactions 
Periodic monitoring of digoxin plasma levels is 
recommended due to increased Cmax and AUC with 
concomitant lenalidomidetherapy. Patients taking 
concomitant therapies such as erythropoietin stimulating 
agents or estrogen containing therapies may have an 
increased risk of venous thromboembolism (VTE).Close 
monitoring of PT and INR is recommended in multiple 
myeloma patients taking concomitant warfarin.9,17,21,22 
Adverse effects 
Serious
17
 
Cardiovascular: Deep venous thrombosis (7.8%) 
Hematologic: Anemia (24.3 %), Febrile neutropenia 
(5.4%), Neutropenia (35.4%), Thrombocytopenia (16% 
to 61.5%)  
Respiratory: Dyspnea (20.2%), Pneumonia (11.5%), 
Pulmonary embolism (3.2%)  
 
Common 
2,7 
Cardiovascular: Peripheral edema (21.1%) 
Dermatologic: Pruritus (41.9%), Rash (35.8%) 
Endocrine metabolic: Hyperglycemia (15%), 
Hypokalemia (11.3%) 
Gastrointestinal: Abdominal pain (12.2%), Constipation 
(38.7%), Diarrhea (48.6%), Indigestion (13.9%), Loss of 
appetite (13.6%), Nausea (23.6%), Vomiting (10.1%), 
Weight decreased (18.2%)  
Hematologic: Leukopenia (8.1%)  
Musculoskeletal: Arthralgia (21.6%), Backache (20.9%), 
Cramp (30.1%), Muscle weakness (15%)  
Neurologic: Dizziness (20.8%), Headache (19.6%), 
Insomnia (32.1%), Peripheral neuropathy (8.1%), 
Tremor (19.7%)  
Ophthalmic: Blurred vision (14.7%)  
Psychiatric: Asthenia (23.4%), Fatigue (31.1%)  
Renal: Dysuria (6.8%)  
Respiratory: Upper respiratory infection (14.9%)  
Others: Fatigue (38.4%), Fever (23.1%) 
Contraindications 
Thalidomide is a known human teratogen that causes 
life-threatening human birth defects or embryo-fetal 
death. Lenalidomideby being a thalidomide analogue, is 
contraindicated for use during pregnancy(Pregnancy 
category X).Women of childbearing potential are also to 
be cautioned for its use unless adequate precautions are 
taken to prevent pregnancy since it runs high risk of 
potential for birth defects.Hypersensitivity to this drug is 
absolute contraindication. 
Precautions 
 Increased mortality: serious and fatal cardiac adverse 
reactions were observed in patients with Chronic 
Lymphocytic leukemia. 
 Second primary malignancies (SPM): higher 
incidences of SPM were observed in controlled trials 
of patients with multiple myeloma. 
 Hepatic failure including fatalities; monitor liver 
function. 
 Serious tumor flare reactions have occurred  during 
investigational use for chronic lymphocytic leukemia 
and lymphoma 
 Patients with renal insufficiency: adjust the starting 
dose of with moderate or severe renal impairment and 
on dialysis 
Indications 
Lenalidomide is a second-generation immunomodulatory 
drug (iMID) currently approved by the US Food and 
Drug Administration (FDA) for the management of 
various hematologic malignancies as below: 
1. Multiple myeloma: On June 29, 2006, FDA granted 
approval to lenalidomide for use in combination 
with dexamethasone in patients with multiple 
myeloma who have received one prior therapy 9. The 
dose of lenalidomide is 25 mg/day orally and 
dexamethasone at a dose of 40 mg/day. On 23 April 
2009, The National Institute for Health and Clinical 
Excellence (NICE) issued a Final Appraisal 
Determination (FAD) approving lenalidomide, in 
combination with dexamethasone, as an option to 
treat patients of multiple myeloma who have 
received two or more prior therapies in England and 
Wales.20,21 
2. Myelodysplastic syndromes: On December 27, 
2005, the U.S. Food and Drug Administration 
granted Subpart H approval (restricted distribution) 
to lenalidomide oral capsules for use in patients with 
transfusion-dependent anemia due to low or 
intermediate-1risk myelodysplastic 
syndromes (MDS) associated with a deletion 5q 
cytogenetic abnormality with or without additional 
cytogenetic abnormalities. It was approved on June 
17, 2013 by the European Medicines Agency for use 
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in low- or intermediate-1-risk myelodysplastic 
syndromes (MDS) patients who have the deletion 5q 
cytogenetic abnormality and no other cytogenetic 
abnormalities, are dependent on red blood cell 
transfusions, and for whom other treatment options 
have been found to be insufficient or inadequate.
22,23
 
3. Mantle cell lymphoma: In June 2013, the U.S. Food 
and Drug Administration approved lenalidomide 
capsules for the treatment of patients with mantle cell 
lymphoma (MCL) whose disease has relapsed or 
progressed after two prior therapies, one of which 
included bortezomib.The recommended dose is 25 mg 
orally once daily on days 1-21 of repeated 28 days 
cycle. FDA approved lenalidomide for this indication 
on June 2013.
7
 
 
Other indications 
Lenalidomide is an active first-line treatment option for 
CLL that is well-tolerated if a conservative approach with 
low doses and slow dose-escalation is used.
24 
Many studies 
have been done on assessing the safety and therapeutic 
profile of lenalidomide in patients with cancers like acute 
myeloid leukemia, prostate carcinoma, renal cell carcinoma, 
B-cell lymphoma, astrocytoma, glioma, hepatocellular 
carcinoma, pancreatic cancer, etc. The lenalidomide has 
possibility of being used as an adjuvant in support of more 
specific immunotherapeutic interventions including 
anticancer vaccines and adoptively transferred cells which 
warrants further investigation.
25 
Lenalidomide is undergoing 
clinical trial for Hodgkin's lymphoma and non-Hodgkin's 
lymphoma, chronic lymphocytic leukemia (CLL) and solid 
tumor cancersof the pancreas.
26,27 
One Phase 3 clinical trial 
being conducted by Celgene in elderly patients with B-cell 
chronic lymphocytic leukemia was halted in July 2013 
when a disproportionate number of cancer deaths were 
observed during treatment with lenalidomide versus patients 
treated with chlorambucil.
28
 
CONCLUSION 
Lenalidomide is an important addition to the treatment 
armamentarium for relapsed or refractory MM, MDS and 
MCL. Lenalidomide is administered in combination with 
low-dose glucocorticoids (most often dexamethasone or 
prednisone), which are well known for their 
immunosuppressive potential. Lenalidomide is more potent, 
more active and less toxic than its parent drug thalidomide.
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